[PET-CT in head and neck cancer]

HNO. 2017 Jun;65(6):504-513. doi: 10.1007/s00106-017-0355-7.
[Article in German]

Abstract

The importance of 18F-fluorodesoxyglucose positron-emission tomography (FDG-PET) for the diagnosis of malignant disease is increasing. On one hand, this is due to the high sensitivity of this method, on the other, because the entire body can be examined. FDG-PET can be particularly advantageous for the diagnosis of head and neck tumors, where tumor staging is an important prognostic parameter and essentially determines the therapeutic regimen. This article presents the different possibilities for combined evaluation with PET and computed tomography (CT) for the diagnosis of patients with head and neck cancer. Special focus is placed on primary staging and tumor follow-up, as well as on the role of PET-CT in the diagnosis of patients with cancer of unknown primary origin (CUP). The use of PET-CT for radiotherapy planning and new aspects of PET technology are also discussed.

Keywords: Cancer staging; Diagnostic imaging; Head and neck neoplasms; Positron emission tomography; Positron emission tomography-computed tomography.

Publication types

  • Review

MeSH terms

  • Evidence-Based Medicine
  • Fluorodeoxyglucose F18*
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Image Enhancement / methods
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18